Controls serum phosphorus. ANDA 203860, held by Invagen Pharms. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 203860 (Sevelamer Carbonate), held by Invagen Pharms, was first approved by FDA on Oct 26, 2017, with 2 approved supplements and 0 published complete response letters.
Sevelamer carbonate is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG · tablet;oral | Sevelamer Carbonate | Rx |
| Dec 28, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 10, 2020 | Supplement 6Manufacturing | Approved | None posted |
| Oct 26, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters